Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
CA 2287552 C · Owner: Pfizer Limited · Inventors: Mathias, John Paul; Bunnage, Mark Edward; Street, Stephen Derek Albert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
There is provided compounds of formula IA and of formula IB (see formula I) (see formula II), wherein R1 R2, R3, R4 and A have meanings given in the description which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 22, 1999 and granted October 7, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 22, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 22, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.